Rosalind Advisors, Inc.

Institutional manager — quarterly 13F holdings, Q ending 2026-03-31

Reported value
$248.9M
Q ending 2026-03-31
Prior quarter
$284.5M
Q ending 2025-12-31
Change
-12.5% QoQ · +21.0% YoY
Positions
38
reported holdings

Largest positions

All 38 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
HoldingTickerTypeValueShares
Delcath Systems, Inc.DCTHShares$30.6M3.3M
Xeris Biopharma Holdings IncXERSShares$18.7M3.2M
Fennec Pharmaceuticals IncFENCShares$17.9M2.9M
Savara IncSVRAShares$17.5M3.2M
Vaxcyte IncPCVXShares$16.9M290K
Eyepoint Pharmaceuticals IncEYPTShares$13.4M1.0M
X4 Pharmaceuticals IncXFORShares$13.3M3.2M
Vor Biopharma IncVORShares$12.5M700K
Mediwound LtdShares$12.1M749K
Verastem IncVSTMShares$11.3M2.1M
Celldex Therapeutics IncCLDXShares$10.5M330K
Biocryst Pharmaceuticals IncBCRXShares$8.8M923K
Cybin IncHELPShares$7.4M1.5M
Cg Oncology IncCGONShares$6.8M100K
Inspiremd IncNSPRShares$6.4M3.9M
Atea Pharmaceuticals IncAVIRShares$6.3M1.2M
Profound Medical CorpPROFShares$5.4M828K
Viridian Therapeutics IncVRDNShares$4.9M250K
Replimune Group IncCall$2.7M1.3M
Polypid LtdShares$2.6M598K
Myomo IncMYOShares$2.6M3.8M
Talphera IncTLPHShares$2.5M3.4M
Ovid Therapeutics IncOVIDShares$2.5M1.1M
Definium Therapeutics IncDFTXShares$2.4M125K
Onkure Therapeutics IncOKURShares$1.8M444K
Lipocine IncLPCNShares$1.8M222K
Neuraxis IncNRXSShares$1.7M286K
Avalo Therapeutics IncAVTXShares$1.1M75K
Annexon IncANNXShares$1.1M200K
Invesco Qqq TrPut$1.1M250K
Aquestive Therapeutics IncAQSTShares$1.0M250K
Spdr S&P 500 Etf TrPut$959K125K
Biofrontera IncBFRIShares$942K1.2M
Kura Oncology IncKURAShares$813K100K
Regentis Biomaterials LtdShares$768K252K
Viridian Therapeutics IncPut$53K264K
Arrivent Biopharma IncCall$0109K
Uniqure NvCall$0296K

Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.